Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Expected outcomes of therapy
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Expected outcomes of therapy

2 evidence topics · 2 sources

Molgramostim: proposed therapeutic goals

“is believed to help restore the surfactant-clearing activity of macrophages, thus improving oxygenation, lung function, and health-related quality of life (HRQoL).” (opens the source at this quote in a new tab)

Outcomes and outcome measures: scoping review

“31 distinct outcomes and 92 corresponding outcome measures.” (opens the source at this quote in a new tab)